Jul 27, 2017 · STAMPEDE is a multigroup, multistage platform trial protocol investigating the efficacy of additional therapy at the time of inception of primary ADT in men with newly diagnosed, locally...

STAMPEDE aims to provide evidence as to what is the best way of treating men with newly diagnosed advanced prostate cancer. Since 2005, almost 12,000 participants joined the trial. We have already reported practice-changing results that show adding docetaxel or abiraterone improve disease control and life-expectancy.

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) is a clinical trial investigating treatments for high risk or terminal prostate cancer. Recruitment started in 2005 and ended in 2022; as of January 2020, …

Dec 1, 2018 · Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial Lancet . 2018 Dec 1;392(10162):2353-2366. doi: 10.1016/S0140-6736(18)32486-3.

Nov 9, 2023 · STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) is a large clinical trial that aims to assess new treatment approaches for people affected by high-risk prostate cancer.

Dec 1, 2018 · Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nov 9, 2023 · The initial results of the STAMPEDE advanced prostate cancer trial showed that progression-free survival is improved when abiraterone acetate and prednisone (AAP) are added to androgen deprivation therapy.

Aug 20, 2015 · The Medical Research Council STAMPEDE trial will add further data on the role of docetaxel in hormone-sensitive prostate cancer; to date, the overall survival in the ADT-alone group in that...

STAMPEDE2 is a clinical trial testing new treatments in men with prostate cancer that has spread to other parts of the body (metastatic prostate cancer). It tests these treatments when the cancer is hormone-sensitive, which means that it is at a stage where it is responsive to treatment with hormone therapy.

Feb 23, 2023 · Results from the STAMPEDE trial of nonmetastatic high-risk prostate cancer strongly support the addition of 2 years of abiraterone to androgen deprivation therapy and radiotherapy among eligible patients.